Institut Paoli Calmettes Ovarian Cancer Database
NCT02869568 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 6000
Last updated 2016-08-17
Summary
Database of Institut Paoli-Calmettes patients diagnosed with ovarian cancer
Conditions
- Ovarian Neoplasms
Interventions
- OTHER
-
Data collection
Sponsors & Collaborators
-
Institut Paoli-Calmettes
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 95 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2000-01-31
- Primary Completion
- 2030-01-31
- Completion
- 2030-12-31
Countries
- France
Study Locations
More Related Trials
-
Evolution of the Therapeutic Care in Ovarian Cancer From 2011
NCT03275298 ·Status: SUSPENDED
-
Genomic BRCA and Extensive ovArian Cancer Testing
NCT04027868 ·Status: COMPLETED
-
Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging
NCT06084195 ·Status: RECRUITING ·Phase: NA
-
Blood Collection From People With Ovarian Cancer
NCT02063464 ·Status: COMPLETED
-
Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors
NCT00488878 ·Status: RECRUITING
-
French Observatory of Rare Malignant Tumors of the Ovary
NCT01304043 ·Status: COMPLETED
-
A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer
NCT02591095 ·Status: COMPLETED ·Phase: PHASE2
-
Development of a Patient Reported Outcome Measure for Advanced Ovarian Cancer Patients Receiving Surgical and Chemotherapy Treatment
NCT05274867 ·Status: UNKNOWN
-
Oxford Ovarian Cancer Predict Chemotherapy Response 01
NCT01770535 ·Status: UNKNOWN
-
Development and Evaluation of a Fertility Preservation Patient Decision Aid for Women With Cancer.
NCT02753296 ·Status: UNKNOWN
-
Circulating Tumor DNA as an Early Marker of Recurrence and Treatment Efficacy in Ovarian Carcinoma
NCT03302884 ·Status: UNKNOWN ·Phase: NA
-
Study of Circulating Tumoral DNA in Ovarian Cancer
NCT01350908 ·Status: COMPLETED ·Phase: NA
-
Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Cancer Cases
NCT01048814 ·Status: COMPLETED
-
Paclitaxel and Carboplatin Combination as 1st Line Treatment in Ovarian Carcinomas
NCT00750386 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Constitution of ex Vivo Ovarian Tumor Models for the Validation of the Interest of Innovative Therapies and the Search for Tumor or Circulating Biomarkers Predictive of Treatment Response
NCT03831230 ·Status: COMPLETED
-
Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian Cancer
NCT03922776 ·Status: TERMINATED ·Phase: NA
-
Microscopic Peritoneal Metastases After Complete Macroscopic Cytoreductive Surgery for Epithelial Ovarian Cancer
NCT03754569 ·Status: COMPLETED ·Phase: NA
-
Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer
NCT01253681 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of Amino Acid Metabolism Changes in Ovarian Cancer
NCT06216496 ·Status: RECRUITING ·Phase: NA
-
Development for the Peritoneal Carcinomatosis Index (PCI) in Ovarian Cancer
NCT01538498 ·Status: COMPLETED
-
The Assessment of Mesothelin Antigen Specific Immunologic Assays in Ovarian Cancer Patients
NCT00173394 ·Status: UNKNOWN
-
Detection of Homologous Recombination Pathway Gene Mutations in Circulating Tumour DNA From BRCA-mutated Ovarian Cancer Patients Receiving First-line PARP Inhibitor Maintenance Therapy
NCT06588322 ·Status: RECRUITING ·Phase: NA
-
Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma
NCT05537844 ·Status: UNKNOWN
-
Evaluation of Chemotherapy Influence on Clinical and Biological Markers of Ovarian Reserve
NCT00712452 ·Status: TERMINATED ·Phase: NA
-
Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors
NCT04675320 ·Status: UNKNOWN